1.
Dajani EZ, Studies on the pharmacology of the industrial
solvent methyl cellosolve.
Society of Experimental Biology and Medicine. Indianapolis, Indiana. October
1968.
2.
Dajani EZ, Mennear JH: Gas chromatographic assay for ethylene
glycol monomethyl ester.
Toxicol Appl Pharmacol 14(3): 618,
1969.
3.
Dajani EZ: Experimental cholelithiasis: Studies on the mouse
and hamster gallstone models.
An invited lecture presented at the Gastrointestinal
Pharmacology Group Symposium on Bile. Philadelphia,
Pennsylvania. November
1970.
4.
Dajani EZ: The technicians' role in toxicological
studies. An invited
lecture presented at the AALAS Symposium on Laboratory Animal
Considerations in Toxicology and Related Disciplines. New Brunswick,
New Jersey. June
1972.
5.
Dajani EZ: Gastric antisecretory and antiulcer actions of
E-prostaglandin analogs.
An invited lecture presented at the Department of Medicine
(Gastroenterology), University of California, San Francisco,
California. April 1974.
6.
Dajani EZ, Roge EAW, Bertermann RE: The effect of
prostaglandin E1 methyl ester and diphenoxylate on canine
duodenal motility in vivo.
Presented at the Midwest Pharmacology Meeting. Ann Arbor,
Michigan. May
1975.
7.
Dajani EZ, Driskill DR, Bianchi RG, Collins PW, Pappo R:
Studies on the biological properties of a prostaglandin analog,
SC-29333, a potent inhibitor of gastric secretion. Presented at the
International Conference on Prostaglandins. Florence, Italy.
May 1975.
8.
Collins PW, Pappo R, Dajani EZ: Application of 1,4 addition
reactions to the synthesis of novel prostaglandins. Presented at the
International Conference on Prostaglandins. Florence, Italy. May
1975.
9.
Dajani EZ, Bianchi RG, Adelstein GW, Yen CH: Studies on the
biological properties of SC-27166, a novel antidiarrheal agent. Philadelphia GI Research
Forum. Philadelphia,
Pennsylvania. October 1975.
10. Dajani EZ,
Driskill DR, Bianchi RG, Collins PW, Pappo R: Studies on the
pharmacology of SC-29333, a potent gastric antisecretory
prostaglandin. Philadelphia GI Research Forum. Philadelphia, Pennsylvania.
October 1975.
11.
Adelstein GW,
Yen CH, Dajani EZ: Synthesis and biology of a novel series of
antidiarrheal agents.
Am Chem Soc Meeting.
Mexico City, Mexico, 1975.
12. Pappo R,
Collins PW, Bruhn MS, Palmer JR, Dajani EZ: Synthesis and biological
properties of 16-hydroxy prostaglandin analogs. Winter Prostaglandin
Conference. Vail, Colorado.
January 1976.
13. Dajani EZ,
Callison DA, Bianchi RG, Driskill DR: Gastric antisecretory effects
of E-prostaglandins in conscious monkeys. Federation Proceedings
35: 539, 1976.
14. Dajani EZ:
Effects of E-prostaglandins on the gastric mucosal barrier. An invited presentation at
the Gastrointestinal Pharmacology Symposium entitled "Drugs and the
Gastric Mucosal Barrier."
Groton, Connecticut.
October 1976.
15. Callison
DA, Dajani EZ, Bertermann RE: Effects of E-prostaglandins on canine
gastric potential differences.
Federation Proceedings 36:595,
1977.
16. Dajani EZ:
Drug research in the pharmaceutical industry: A pharmacologist's
point of view. An
invited series of continuing medical and pharmaceutical education
lectures presented at the Kuwait Ministry of Health, Kuwait. November
1977.
17. Driskill
DR, Colton DG, Phillips EL, Poy P, Dajani EZ: Effect of SC-29333 on
gastric mucosal blood flow and serum gastrin in the dog. Federation
Proceedings 37: 459, 1978.
18. Callison
DA, Dajani EZ, Bianchi RG: Gastric antisecretory actions of
propantheline bromide and metiamide in conscious rhesus
monkeys. Federation
Proceedings 37: 460, 1978.
19. Dajani EZ:
Perspective on the pharmacology of antidiarrheal drugs. An invited presentation at a
1978 ASPET Symposium entitled "Current Concepts of Gastrointestinal
Motility." Atlantic
City, New Jersey. April
1978.
20. Dajani EZ,
Roge EAW, Bertermann RE, Schweingruber FL: Gastrointestinal motility
effects of PGF2 alpha in the dog. 7th International Congress
of Pharmacology. Paris, France. July
1978.
21. Dajani EZ,
Roge EW, Bertermann RE, Schweingruber FL: Reversal of
gastrointestinal motility actions of PGF2 alpha by
naloxone. 7th
International Congress of Pharmacology. Paris, France. July
1978.
22. Bianchi RG,
Dajani EZ, Calhoun DW: Synergistic actions of propantheline bromide,
cimetidine and thiopropazate in the prevention of stress ulcer
formation in rats.
Pharmacologist 20:209, 1978.
23. Dajani EZ:
Pharmacology of anticholinergic drugs. Invited lecture presented at
The Northern Illinois Orthodontic Study Group. Chicago, Illinois. October 1978.
24. Adelstein
GW, Yen CH, Dajani EZ, Bianchi RG: Potent analogs of Lomotil;
separation of constipating and analgesic properties. Amer Chem Soc Great Lakes
Regional Meeting.
Rockford, Illinois.
June 1979.
25. Dajani
EZ: Perspective on the pharmacology of gastric
antisecretory
and antiulcer drugs.
An invited lecture presented at the Amer Chem
Soc Symposium on Peptic Ulcer, Great Lakes Regional
Meeting
Rockford, Illinois.
June 1979.
26. Woods EM,
Dajani EZ, Roge EW, Bertermann RE, Schweingruber FL: Naloxone
reversal of drug-induced diarrhea in mice. Pharmacologist
21:175, 1979.
27. Dajani EZ,
Bianchi RG, Casler JJ, Weet JF: Gastric antiulcer and antisecretory
effects of carbenoxolone, aldosterone and desoxycorticosterone in
rats. Pharmacologist 21:176, 1979.
28. Bianchi RG,
Dajani EZ, Casler JJ, Calhoun DW: Synergistic actions of
propantheline bromide with cimetidine and thiopropazate
hydrochloride in the inhibition of gastric secretion in rats. Pharmacologist
21:176, 1979.
29. Dajani EZ:
Prostaglandins and the gut: An update. An invited lecture presented
at the ASPET Symposium entitled "Recent Developments in
Gastrointestinal Pharmacology." Portland, Oregon. 1979.
30. Dajani EZ:
Perspective on the pharmacology of antiulcer drugs: An update. Grand Rounds presented at
the Department of Medicine, Northwestern University. Chicago, Illinois. November
1979.
31. Driskill
DR, Dajani EZ, Phillips EL, Collins PW, Pappo R: Effects of a
prostaglandin analogue, SC-30249, on canine gastric secretion. Federation Proceedings
39(3): 563, 1980.
32.
Dajani EZ:
Comparison between the pharmacology of gastric and duodenal
antiulcer drugs. An
invited presentation at a symposium entitled "Duodenal and Gastric
Ulcers - Pathogenesis and Pharmacology," co-sponsored by Society of
Pathology and ASPET.
Anaheim, California.
April 1980.
33. Bianchi RG,
Dajani EZ, Casler JJ: Gastric antiulcer and antisecretory effects of
bismuth salts in the rat.
Pharmacologist 22:168, 1980.
34. Gullikson
GW, Dajani EZ, Bianchi RG: Reversal of deoxycholate-induced
intestinal fluid secretion by lidamidine. Pharmacologist
22:168, 1980.
35. Yen CH,
Bianchi RG, Dajani EZ: Synthesis and biological activities of
substituted quinuclidines.
Amer Chem Soc Meeting.
Chicago, Illinois.
January 1981.
36. Dajani EZ:
Pharmacology of the prostaglandin analogue SC-29333. International
Congress on Stomach Diseases, University of Antwerp. Antwerp, Belgium. May
1981.
37.
Dajani EZ:
Prostaglandins and the gastrointestinal tract. Grand Rounds, Hines VA
Hospital. Hines,
Illinois. May 1981.
38.
Kessler L, Bianchi RG, Callison DA, Dajani EZ: Prevention of
duodenal ulcer formation in the cat by E-prostaglandins. Pharmacologist
23:121, 1981.
39. Bianchi RG,
Casler JJ, Dajani EZ: Gastric antisecretory and antiulcer activity
of
SC-29333: A
synthetic E-prostaglandin analog. Pharmacologist
23:121, 1981.
40. Gullikson
GW, Jasty V, Dajani EZ: Effect of lidamidine on deoxycholate-induced
histological and permeability changes in canine jejunum. Pharmacologist
23:122, 1981.
41. Dajani EZ:
Perspectives on the pharmacology of antiulcer drugs. An invited lecture presented
at a symposium entitled "Recent Advances Against Duodenal and
Gastric Ulcer Disease," 13th Lithuanian American Medical
Association. Chicago,
Illinois.
September 1981.
42. Collins PW,
Dajani EZ, Pappo R, Gasiecki AF, Bianchi RG, Woods EM: Synthesis and
gastric antisecretory properties of 4,5-unsaturated derivatives of
15-deoxy-16-hydroxyl-16-methyl prostaglandin
E1. Amer
Chem Soc 183:62, 1982.
43. Pitzele BS,
Kellar P, Kessler L, Sanner J, Woods EM, Dajani EZ: Quaternary
ammonium analogs of an H2-receptor antagonist. Amer Chem Soc 183:
58, 1982.
44. Dajani EZ:
Perspectives on the pharmacology of misoprostol, a synthetic
PGE1 analogue.
An invited lecture presented at the Gordon Research
Conference on Medicinal Chemistry, Colby-Sawyer College. New London, New
Hampshire. August
1982.
45. Dajani EZ,
Collins PW, Bianchi RG, Woods EM, Colton DG, Driskill DR, Pappo R:
Gastrointestinal pharmacology of misoprostol: A novel antiulcer
agent. Invited lecture,
Department of Pharmacology, University of Wisconsin. Madison,
Wisconsin. April
1983.
46. Gullikson
GW, Anglin C, Kessler L, Smeach S, Crowder S, Bauer R, Dajani EZ:
Misoprostol prevents aspirin-induced damage in canine Heidenhain
pouches. Gastroenterology 84:1176,
1983.
47. Dajani
EZ:
Prostaglandins.
An invited presentation, Chicago Society of
Gastroenterology.
Chicago, Illinois.
March 1984.
48. Dajani
EZ: Prostaglandins in
gastroenterology. An
invited lecture (principal speaker), European Association for
Gastro-Camera, Diagnosis and Endoscopy. Innsbruck, Austria. March
1984.
49. Collins PW,
Gasiecki AF, Decktor D, Dajani EZ, Woods EM, Bianchi RG: Alpha chain
unsaturated derivatives of 16-hydroxy prostaglandins. Amer Chem Soc,
National Medicinal Symposium, June 1984.
50. Dajani EZ:
Antidiarrheal drugs. An
invited presentation delivered at a symposium entitled "Newer
Gastrointestinal Drugs," sponsored by The Amer Chem Soc.
Philadelphia, Pennsylvania.
August 1984.
51. Tapper EJ,
Dajani EZ, Polk RC: Dose-response duodenal ulcer healing by
prostaglandin E1 analog. International Congress of
Gastroenterology.
Lisbon, Portugal.
September 1984.
52. Agrawal NM,
Godiwala T, Arimura A, Dajani EZ: Cytoprotection by prostaglandin
E1 analog on ethanol-induced gastric mucosal damage in
man. Amer J
Gastroenterology 79: 824, 1984.
53. Dajani EZ:
Non-prostanoids as cytoprotective agents. An invited presentation,
Mexican Gastroenterological Association Meeting. Guadalajara, Mexico. December
1984.
54. Dajani EZ:
Mucosal cytoprotection: Clinical models. An invited presentation,
Mexican Gastroenterological Association Meeting. Guadalajara,
Mexico. December
1984.
55. Dajani EZ:
Recent advances in the pathophysiology of peptic ulcer disease. An
invited presentation, European Association for Gastroenterology and
Endoscopy, 17th Congress.
Berlin, West Germany.
March 1985.
56. Dajani EZ,
Bianchi RG, Colton DG, Callison DA, Driskill DR, Phillips EL,
Kessler L, Gullikson GW, Woods EM, Collins PW, Pappo R: Perspectives
on the pharmacology of misoprostol. An invited presentation,
Fifth International Conference on Experimental Ulcer. Boston, Massachusetts. May 1985. Dig Dis Sci 30: 371,
1985.
57. Assad RT,
Dodd DC, Dajani EZ: Effect of misoprostol, a prostaglandin
E1 analog, on epithelial proliferation of canine fundic
mucosa. Gastroenterology 88: 1310,
1985.
58. Assad RT,
Dodd DC, Dajani EZ: Effects of misoprostol, a prostaglandin
E1 analog, on DNA synthesis of canine fundic mucosa. Gastroenterology
88:1310, 1985.
59. Agrawal NM,
Godiwala T, Arimura A, Dajani EZ: Adaptive cytoprotection of the
human gastric mucosa in response to ethanol injury. Gastroenterology
88:1496, 1985.
60. McGuigan
JE, Chang Y, Deysach L, Dajani EZ: Serum gastrin in patients with
duodenal ulcer treated with misoprostol. Gastroenterology 88:1496,
1985.
61. Pitzele BS,
Yu SS, Hamilton RW, Moorman AE, Gullikson GW, Bianchi RG, Palicharla
P, Dajani EZ: Potential antisecretory antidiarrheals, alpha-2
adrenergic agonists related to clonidine. Amer Chem Soc. Chicago,
Illinois. September
1985.
62.
Agrawal NM, Godiwala T,
Arimura A, Dajani EZ: Comparative cytoprotection against ethanol-induced
gastric mucosal damage: Misoprostol vs. cimetidine. Amer J of Gastroenterology
80: 860, 1985.
63. Larsen KE,
Dajani EZ, Muka M: Effects of misoprostol, 16, 16-dimethyl
PGE2 and cimetidine on mucosal blood flow and oxygen
consumption in the dog ex vivo gastric chamber. Dig Dis Sci 31:142S,
1986.
64. Agrawal NM,
Godiwala T, Arimura A, Dajani EZ: Comparative effects against
alcohol insult: Misoprostol vs. cimetidine. Dig Dis Sci 31:142S,
1986.
65. McGuigan
JE, Chang Y, Dajani EZ: Effect of misoprostol, an antiulcer
prostaglandin, on serum gastrin in patients with duodenal
ulcer. Dig Dis Sci
31:PS120, 1986.
66. Dajani EZ:
Pharmacology of misoprostol.
Three lectures delivered in Birmingham, Leeds and London,
U.K., as part of regional continuing medical education symposia
entitled "Prostaglandins in Peptic Ulcer." February
1986.
67. Dajani EZ:
Cytoprotection and acid peptic diseases. An invited presentation,
European Association for Gastroenterology and Endoscopy, 18th
Congress. Berlin, West Germany. March
1986.
68. Gullikson
GW, Anglin C, Kessler L, Smeach S, Bauer R, Dajani EZ: Misoprostol
prevents aspirin-induced changes in potential difference and
associated damage in canine Heidenhain pouches. An invited presentation,
Canadian Association of
Gastroenterology.
Toronto, Canada.
April 1986.
69. Dajani EZ:
The role of prostaglandins in the maintenance of mucosal
integrity. An invited
presentation, Canadian Association of Gastroenterology. Toronto, Canada. April
1986.
70. Dajani EZ:
Prostaglandins and their actions on the gastrointestinal tract.
Royal Australian College of Physicians Satellite Seminar on
Prostaglandins. Hobart,
Tasmania. May
1986.
71. Dajani EZ:
Prostaglandins: Pharmacology, mechanisms and applications in acid
peptic diseases. An
invited presentation, Seventh Icelandic Congress of Internal
Medicine. Reykjavik,
Iceland. May
1986.
72.
Dajani EZ: Perspective on the gastric antisecretory effects
of misoprostol in man.
Sixth International Conference on Prostaglandins and Related
Compounds. Florence,
Italy. June
1986.
73.
Dajani EZ:
Gastrointestinal cytoprotective activities of misoprostol: Clinical
efficacy overview.
Sixth International Conference on Prostaglandins and Related
Compounds. Florence,
Italy. June
1986.
74.
Reimann HJ, Wendt P. Blueml G, Schmidt U, Ohe MVD, Dajani EZ,
Wehrschütz E: Misoprostol prevents damage to the gastroduodenal
mucosa by stabilizing the mast cells. Sixth International
Conference on Prostaglandins and Related Compounds. Florence,
Italy. June
1986.
75. Dajani EZ:
Clinical cytoprotective actions of misoprostol. An invited
presentation, Italian Society of Gastroenterology. Verona,
Italy. June
1986.
76. Dajani EZ:
Prostaglandins in acid peptic disorders. An invited lecture presented
at a post-graduate course sponsored by the European Society of
Gastroenterology and Endoscopy. Cologne, W. Germany. October
1986.
77. Dajani EZ:
Misoprostol: Pharmacology, mechanism and applications in peptic
ulcer disease. An
invited lecture presented at a symposium entitled "International
Symposium on Cytoprotection of the Gastroduodenal Mucosa,"
Inter-American Society of Clinical Pharmacology and
Therapeutics/Latin American Association of Pharmacology. Buenos Aires,
Argentina. November
1986.
78. Dajani EZ:
Overview of misoprostol clinical safety. An invited lecture presented
at a symposium entitled "Prostaglandins and Peptic Ulcer Disease,"
Hong Kong Society of Internal Medicine. Hong Kong. December
1986.
79. Dajani EZ:
Pharmacology of misoprostol: Antisecretory plus mucosal protective
activity for an antiulcer agent. An invited lecture presented
at the European Society of Gastroenterology and Endoscopy, Milan,
Italy, June 1986.
Italian Journal of Gastroenterology 19 (Suppl. 3):
19S, 1987.
80. Dajani EZ:
Prostaglandins in gastroenterology. An invited presentation.
Chinese Society of Gastroenterology. Kunming, People's Republic
of China. November
1987.
81. Dajani EZ:
Prostaglandins: An update. An invited presentation. American College of
Physicians PostGraduate Course. Keystone, Colorado. February
1988.
82. Dajani EZ:
Prostaglandins and NSAIDs gastropathy. An invited
presentation. Pakistan
Society of Gastroenterology and Gastrointestinal Endoscopy. Rawalpindi, Pakistan. March
1988.
83. Dajani EZ:
Prostaglandins in gastroenterology. An invited
presentation. European
Society of Gastroenterology.
Milan, Italy.
April 1988.
84. Dajani EZ,
McGuigan JE, Chang Y: Effect of the antiulcer prostaglandin
misoprostol on serum gastrin in patients with duodenal ulcer. Postgraduate Medical J
64: 79(Abstract), 1988.
85. Dajani EZ:
Prostaglandins and mucosal protection: An update. An invited
presentation. Amer
Association of Colleges of Pharmacy. Chicago, Illinois. July
1988.
86. Dajani EZ,
Lanza F: Endoscopic comparison of the protective effects of
misoprostol, cimetidine and sucralfate on nonsteroidal
anti-inflammatory drugs induced gastrointestinal mucosal
injury. Endoscopy
20: 83 (Abstract), 1988.
87. Dajani EZ:
Prostaglandins and NSAIDs gastropathy. An invited presentation. 1988 International
Congresses of Gastroenterology and Digestive Endoscopy. Rome, Italy. September
1988.
88. Dajani
EZ:
Prostaglandins.
An invited presentation. The USSR Cardiology Research
Center at the USSR Academy of Medical Sciences. Moscow, USSR. February
1989.
89. Dajani EZ:
Protective and therapeutic effects of prostaglandins. An invited presentation
given at a Symposium entitled "NSAID Damage of the Upper
Gastrointestinal Tract." Third Interscience World Conference on
Inflammation. Monte
Carlo, Monaco. March
1989.
90.
Dajani EZ:
Prostaglandins and nonsteroidal anti-inflammatory drugs:
Pharmacology and mechanism of action. An invited
presentation.
Prostaglandins Telesymposium. University of Puerto
Rico. San Juan, Puerto
Rico. May
1989.
91. Dajani EZ:
Prostaglandins in surgical diseases. An invited
presentation.
Department of Surgery.
Rush-Presbyterian St. Lukes Medical Center. Chicago,
Illinois. June
1989.
92. Dajani EZ:
Overview on the mechanisms of cytoprotection by misoprostol. An invited presentation at
the International Symposium on Cell Injury and Cytoprotection. Harvard Medical School.
Boston, Massachusetts.
July 1989.
93. Dajani EZ:
Prostaglandins and the esophagus: Pharmacological and therapeutic
perspectives. An invited presentation. International Symposium on
Esophageal Diseases.
Taormina, Italy.
September 1989.
94. Dajani EZ:
Prostaglandins and nonsteroidal anti-inflammatory drugs:
Pharmacology, mechanisms of action and future prospects. An invited
presentation.
International Symposium on Esophageal Diseases. Taormina, Italy. September
1989.
95.
Dajani EZ:
Prostaglandins and mucosal protection: Current and future
perspectives. Visiting
Professor Lecture Series, Department of Pharmacology and
Toxicology. Purdue
University, West Lafayette, Indiana, November
1989.
96. Downie WW,
Dajani EZ: NSAID-induced gastropathy: Treatment. Second International
Congress of Rheumatology.
Manila, Philippines.
December 1989.
97.
Dajani EZ:
Prostaglandins: Visiting Professor. Departments of Medicine and
Surgery, University of Pittsburgh, Pittsburgh, Pennsylvania,
December 1989.
98. Dajani EZ:
Prostaglandins and gastroenterology. An invited
presentation. Louisiana
Gut Club, New Orleans, Louisiana, February 1990.
99. Dajani
EZ: Prostaglandins: Current and future perspectives regarding
gastric mucosal protection. American College of
Physicians. Post
Graduate Course, Keystone, Colorado, February 1990.
100. Dajani EZ:
Historical perspectives on the discovery and development of
misoprostol: A pharmacologist odyssey. An invited
presentation. Second
International Symposium on Experimental and New Therapeutic
approaches to Ulcer Diseases.
Pecs, Hungary, July 1990.
101.
Dajani EZ:
Pharmaceutical industry perspectives on the discovery and
development of antiulcer drugs. Chairman of a Round Table
Discussion. Presented
at the Second International Symposium on Experimental and New
Therapeutic Approaches to Ulcer Disease. Pecs, Hungary, July
1990.
102. Dajani EZ:
Prostaglandins: Current and future medical developments. An invited
presentation.
Departments of Medicine and Surgery, Hines Veteran
Administration Medical Center.
Hines, Illinois, July 1990.
103. Dajani EZ:
Prostaglandins: Past, present and future. An invited presentation
celebrating the tenth anniversary of Donald E. Wilson, MD as a
Chairman of the Department of Medicine, State University of New
York, Health Science Center, Brooklyn, NY, September,
1990.
104. Agrawal NM,
Dajani EZ, Stromatt S, Brown J: Misoprostol vs. sucralfate for the
prophylaxis of NSAID-induced gastric mucosal damage: Result of acute
and chronic administration.
Amer J Gastroenterol 85 (9): 1228 (Abstract),
1990.
105. Dajani EZ:
Prostaglandins in acid peptic disorders. An invited
presentation. Second
Symposium on Experimental Ulcer Disease. Otocec (Slovenia),
Yugoslavia, November 1990.
106.
Dajani EZ:
Prostaglandins in acid peptic disorders: An overview of the
worldwide clinical experience: An invited lecture. American College of
Physicians PostGraduate Course, Keystone, Colorado, February
1991.
107. Agrawal NM,
Stromatt S, Dajani EZ: Comparative efficacy of misoprostol and
sucralfate in preventing gastric ulcers in patients on chronic
NSAIDs therapy: Role of gastric erosion as a predictor for the
development of ulcers.
Seventh International Conference on Experimental Ulcer. Berlin, Germany, October
1991.
108. Dajani EZ,
Agrawal NM: Prevention of NSAID-induced gastric damage: Effect of
prostaglandins and mucosal coating compounds. Joint Meeting of the
Mediterranean Society of Clinical Pharmacology and the Italian
Society of Gastroenterology.
Venice, Italy, October, 1991.
109. Agrawal NM,
Dajani EZ: Misoprostol is superior to sucralfate in preventing
NSAID-induced gastric ulcer in patients with osteoarthritis:
Importance of erosions. J Association for Academic Minority
Physicians 2: 179, 1991.
110. Agrawal N,
Meckstroth S, Dajani EZ: Clinical significance of gastric erosions
as a predictor of NSAID-induced ulcers. Gastroenterology
102:Al, 1992.
111. Dajani EZ:
Clinical use of prostaglandins in ulcer therapy. An invited
presentation. FASEB/AGA
Summer Research Conference entitled "Molecular Basis of Gastric
Mucosal Defense."
Copper Mountain, Colorado, July 1992.
112. Dajani, EZ:
Predictive Models For the Evaluation of Anti-ulcer and
Cytoprotective Drugs in Healthy Human Subjects. An invited presentation.
Italian Society of Pharmacology: Clinical Pharmacology Section,
Udine, Italy, September 1993.
113. Dajani, EZ:
Prostaglandins in Gastroenterology: An Update. Invited
presentation. Second
Osaka International Symposium on Gastroenterology. Osaka, Japan, November
1993.
114. Dajani, EZ:
Prostaglandins in Medicine. Visiting Professor Lecture
Series. Invited
presentation. Osaka
City University Medical
School. Osaka, Japan,
November 1993.
115. Kobayashi K, Dajani EZ, Itoh M,
Arakawa T: Second Osaka International symposium on Gastroenterology:
Symposium Synopsis. Dig
Dis Sci 39 (4): 897-898, 1994.
116.
Dajani EZ, Agrawal NM: Prevention
and treatment of ulcers induced by nonsteroidal anti-inflammatory drugs. Invited Presentation. 8th International Conference
on Ulcer Research. Kyoto, Japan, November 1994.
An abstract of this presentation was published in Digestion 55 (suppl 2): 7,
1994.
117.
DaCosta J, Vega
KJ, Trotman BW, Cunniff D, Dajani EZ: Topical misoprostol therapy
for idiopathic HIV esophageal ulceration. Am J Gastroenterol 91:
1886, 1996.
118.
Vega KJ, DaCosta J,
Bollu J, Trotman BW, Kloser P, Cunnif D, Dajani
EZ: Topical misoprostol
therapy for HIV idiopathic esophageal
ulceration: Case report and literature review. J Association
for
Academic Minority Physicians 7 (4): XXIX,
1996.
119.
Dajani EZ: NSAIDs and H. pylori in peptic ulcers.
Is there a connection?
An invited presentation. Ministry of
Public
Health, Abu Dhabi, United Arab Emirates, December 1997.
120. Dajani EZ:
Treatment and prevention of NSAID-induced ulcers. An
invited presentation. Ministry of Public Health, Abu
Dhabi, United Arab
Emirates, December 1997.
121. Larsen KR,
Dajani EZ, Dajani NE, Dayton MT: Effects of tolcapone and
carbidopa/L-DOPA on intestinal electrolyte and fluid transport in
dogs. Gastroenterology 114: SO135, 1998.
122. Dajani EZ,
Taylor J, Dajani NER, Mir GN: Investigation of the analgesic action
of CT-3
[1’1’-dimethyl-heptyl-Delta-8-THC-11-oic
acid] in mice: A novel, orally effective cannabinoid. FASEB Journal
13: A1108, 1999.
123.
Dajani EZ, Larsen KR, Dajani NE, Neelman SD, Taylor MS,
Dayton
MT: Analgesic and ulcerogenic actions of CT-3
[1’1’-dimethyl-heptyl-
Delta-8-THC-11-oic acid] in rats: A novel, orally
effective
cannabinoid. FASEB Journal 13: A1108, 1999.
124.
Dajani EZ: NSAIDs, Prostaglandins and gastrointestinal
mucosal
defense. Invited presentation. Guilio Bertaccini Memorial
Symposium,
University of Parma, Parma, Italy. May 1999.
125.
Dajani EZ: Regulatory considerations in the drug development
process.
Invited presentation. Chicago Biotech Network. Chicago, Illinois.
June
1999.
126.
Dajani EZ: Gastroesophageal reflux disease (GERD):
Pathophysiological and pharmacological considerations.
Invited speaker at a symposium entitled Gastroesophageal
Reflux
Disease, sponsored by the Association for Academic Minority
Physicians, Washington, DC. October 1999.
127.
Dajani EZ, Shahwan T, Dajani NE: Prostaglandins and brain-gut
axis.
Invited presentation. The Second International Symposium for
Brain-
Gut Axis. Basic and Clinical Aspects. Krakow, Poland.
November
2003.
128.
Dajani EZ, Konturek SJ: Prostaglandins and Brain-Gut Axis:
Concluding remarks. Invited presentation. The Second International
Symposium for Brain-Gut Axis. Basic and Clinical Aspects, Krakow,
Poland.
November 2003.
